MCLAUGHLIN KEVIN F 4

4 · Vericel Corp · Filed Feb 14, 2025

Form 4

Period: 2025-02-12

Director

Transactions

Exercise/Conversion
Common Stock
2025-02-12$2.76/sh+1,000$2,760→ 12,900 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-02-12+1,000→ 14,000 total
Exercise: $2.76Exp: 2026-05-04→ Common Stock (1,000 underlying)
Exercise/Conversion
Common Stock
2025-02-12$3.74/sh+6,000$22,440→ 17,900 total
Sale
Common Stock
2025-02-12$55.47/sh−6,000$332,820→ 11,900 total
Sale
Common Stock
2025-02-12$55.43/sh−1,000$55,430→ 11,900 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-02-12+6,000→ 0 total
Exercise: $3.74→ Common Stock (6,000 underlying)

Footnotes (4)

[F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.
[F2]These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017.
[F3]These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025
[F4]These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

Documents

1 file